Table 1.

DAA agents

Medication	Dose	Clearance	Target of Action	Use in CKD Stages 4 and 5
Sofosbuvir	400 mg daily	Renal =81%; GI=15%	NS5B	eGFR=15–29 ml/min: not recommended; eGFR<15 ml/min: not recommended; limited data available
Simeprevir	150 mg daily	Renal <1%; GI=91%	NS3A/4A	eGFR=15–29 ml/min: dose adjustment not required; eGFR<15 ml/min: not recommended; limited data available
Ledipasvir	90 mg daily	Renal =1%; GI=86%	NS5A	eGFR=15–29 ml/min: dose adjustment not required; eGFR<15 ml/min: not recommended
Ombitasvir/paritaprevir/ritonavir; dasabuvir	12.5/75/50 mg ×2 tablets; 250 mg ×2 tablets	Renal <2%; GI=90%	NS5A/NS3A/4A/CYP3A; NS5B	eGFR=15–29 ml/min: dose adjustment not required; eGFR<15 ml/min: dose adjustment not required; not studied in patients on dialysis; limited data
Grazoprevir/elbasvir	100/50 mg daily	Renal <1%	NS3/4A NS5A	eGFR=15–29 ml/min: dose adjustment not required; eGFR<15 ml/min: dose adjustment not required; dialysis population studied
Daclatasvir	60 mg daily; used with sofosbuvir	Renal =7%; GI=88%	NS5A	eGFR=15–29 ml/min: dose adjustment not required; eGFR<15 ml/min: dose adjustment not required

GI, gastrointestinal.